Promotes in-vivo tumor-attacking killer T-cells to facilitate cancer treatment Promotes in-vivo tumor-attacking killer T-cells to facilitate cancer treatment
Go here to see the original:
PDS Biotech Releases White Paper Detailing the Potential of the Versamune® Platform in Overcoming a Major Limitation of Immuno-Oncology
- Phase 3 REGAL Study of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Patients Underway in United States and Europe -
See the original post here:
SELLAS Life Sciences Highlights 2020 Business and Clinical Progress and 2021 Milestones
Received Clinical Trial Authorization to Commence Cancer Appetite Recovery Phase I/II Clinical Study of ART27.13 in UK
Read this article:
Artelo Biosciences Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Update
DAVIS, Calif., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Marrone Bio Innovations (NASDAQ: MBII) (MBI), a global provider of bio-based crop protection and plant health products, today announced that it recently received approval for Grandevo WDG Bioinsecticide for use in New Zealand and Chile. Grandevo WDG and Grandevo CG have also been approved for use on hemp by the U.S. Environmental Protection Agency (EPA).
The rest is here:
Global Adoption of Biologicals Accelerates as Marrone Bio’s Grandevo® WDG Bioinsecticide is Approved for Use in New Zealand, Chile and on Hemp in...
Approvals Allow Company to Seek Sales to European Market
Go here to read the rest:
One World Pharma Receives Colombian Approval for Five THC Strains
Live video webcast with President and CEO, Gilles Gagnon on Wednesday, January 20th at 11:15 AM ET Live video webcast with President and CEO, Gilles Gagnon on Wednesday, January 20th at 11:15 AM ET
See the rest here:
Ceapro Inc. to Present at NobleCon17
MONTREAL, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer and Dr. Christian Marsolais, Senior Vice President and Chief Medical Officer will present at the B. Riley Virtual Oncology Investor Conference on Wednesday, January 20, 2021 at 3:30 p.m. ET.
Link:
Theratechnologies to Present at the B. Riley Securities Virtual Oncology Investor Conference
RoosterBio’s innovative hMSCs and bioprocess media systems, coupled with Sartorius’s scalable closed system bioreactor, downstream processing, and analytics, offers end-to-end hMSC manufacturing solutions for the field of regenerative medicine. RoosterBio’s innovative hMSCs and bioprocess media systems, coupled with Sartorius’s scalable closed system bioreactor, downstream processing, and analytics, offers end-to-end hMSC manufacturing solutions for the field of regenerative medicine.
Read this article:
RoosterBio Partners with Sartorius to Advance Cell and Gene Therapy Manufacturing
BELTSVILLE, Md., Jan. 14, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of Dr. Han Myint, MD, FACP as chief medical officer. Dr. Myint will oversee the clinical development of key products in NextCure’s product pipeline, including NC318, a first-in-class immunomedicine, targeting Siglec-15 (S15), and NC410, recombinant LAIR-2 fusion protein designed to block immune suppression mediated by the immune modulator LAIR-1. Prior to joining NextCure, Dr. Myint held senior roles at both Celgene (a Bristol Myers Squibb Company) and NexImmune Inc.
Read the original post:
Dr. Han Myint Appointed as NextCure’s Chief Medical Officer
